Nemolizumab improved most common symptoms in moderate, severe atopic dermatitis

WASHINGTON – Nemolizumab, an anti-interleukin-31 receptor A monoclonal antibody, was shown to rapidly and consistently improve pruritus, dermatitis, and sleep disturbance in patients with previously uncontrolled moderate-to-severe atopic dermatitis in a phase II, randomized, double-blind,...
Source: Skin and Allergy News - Category: Dermatology Source Type: news